Business Daily from THE HINDU group of publications
Friday, Oct 30, 2009
ePaper | Mobile/PDA Version | Audio | Blogs
Business Daily from THE HINDU group of publications Friday, Oct 30, 2009 ePaper | Mobile/PDA Version | Audio | Blogs |
|
|
|
|
|
Home Page
-
Stocks Markets - Recommendation
We recommend a sell in the stock of Aurobindo Pharma from a short-term perspective. It is perceptible from the charts of the stock that it has been on a long-term uptrend from November 2008 low of Rs 101.6. It was on an intermediate-term uptrend from July low of Rs 406 till its October high of Rs 891. However, triggered by the negative divergence displayed in the daily relative strength index (RSI) and moving average convergence and divergence indicator (MACD), the stock’s direction has reversed. On October 29, it tumbled 5 per cent penetrating a key support at Rs 810 as well as intermediate-term up trendline, reinforcing its downtrend. Moreover, the weekly RSI has also displays negative divergence and is declining from the overbought territory. We are bearish on the stock from a short-term perspective. We anticipate it to decline further until it hits our price target of Rs 695 in the approaching sessions. Traders with a short-term perspective can sell the stock while maintaining a stop-loss at Rs 815. Yoganand DPfizer acquires rights to 60 products of Aurobindo Aurobindo Pharma-Pfizer deal: Positive for both companies Aurobindo Pharma promoters pledge 39% of equity More Stories on : Stocks | Recommendation
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2009, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|